Immunology · IL-23Regulatory Approvalregulatorymid-term

FDA Accepts Supplement for SKYRIZI (Risankizumab) by AbbVie

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AbbVie15 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/3/2026, 6:31:03 AM

Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for SKYRIZI is a significant regulatory milestone that could bolster AbbVie's competitive position in the immunology sector. This development warrants close monitoring as it may influence market dynamics and competitor strategies. Regulatory context from FDA (FDA AP — SKYRIZI (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (7 high-relevance).

Strategic Assessment

Strategic focus on the development and marketing of SKYRIZI could strengthen AbbVie's portfolio in immunology. The strongest clinical anchor is Pomegranate Dietary Supplements in AUD and ALD (ClinicalTrials.gov), moderate corpus alignment. In Immunology · IL-23, 8 regulatory and 2 competitive items passed relevance filtering for AbbVie.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector. This acceptance may enhance AbbVie's position in the IL-23 inhibitor market, potentially impacting competitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SKYRIZI (SUPPL) (FDA). Entity match (abbvie). Relevant agencies in corpus: FDA, MHRA. The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval timeline and outcomes remain uncertain.

Key Risks

Elevated medium regulatory exposure for AbbVie could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, the supplemental application could enhance AbbVie's market share in the IL-23 inhibitor space, potentially leading to increased revenue from SKYRIZI.
Upside for AbbVie may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Strategic focus on the development and marketing of SKYRIZI could strengthen AbbVie's portfolio in immunology.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's decision on the supplemental application and any competitive responses.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SKYRIZI (SUPPL)
FDAhigh relevance
Entity match (abbvie)
FDA document
View source
FDA AP — SKYRIZI (SUPPL)
FDAhigh relevance
Entity match (abbvie)
FDA document
View source
FDA AP — SKYRIZI (SUPPL)
FDAhigh relevance
Entity match (abbvie)
FDA document
View source
FDA AP — RINVOQ LQ (SUPPL)
FDAhigh relevance
Entity match (abbvie)
FDA document
View source
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
FDAhigh relevance
Regulatory pathway relevance (supplement)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Data Standards Program Strategic Plan and Board
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Notice: Register of authorised online sellers of medicines in Northern Ireland
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

Pomegranate Dietary Supplements in AUD and ALD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Oral Nutritional Supplement in Adults With or at Risk of Malnutrition
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Automated Daytime Adaptive Deep Brain Stimulation Parameter Optimization in Patients Implanted With Percept Neurostimulator
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and Performance Evaluation of the RonovoTM Robotic Surgical Platform in Oncological Procedures
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AbbVie
SKYRIZI

Commercial impact

medium

If approved, the supplemental application could enhance AbbVie's market share in the IL-23 inhibitor space, potentially leading to increased revenue from SKYRIZI.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval timeline and outcomes remain uncertain.

What to watch

Monitor the timeline for the FDA's decision on the supplemental application and any competitive responses.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.